Tacrolimus enema for left-sided ulcerative colitis
Part of Digestive system clinical trials.
This trial tests a tacrolimus enema (a liquid given rectally) for adults with mild to moderately active left-sided ulcerative colitis who haven't gotten better with standard treatments. It aims to see if this new approach can help reduce symptoms like rectal bleeding and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have left-sided ulcerative colitis that is mild to moderately active (not severe), confirmed by a colonoscopy.
- You have tried at least one standard treatment (like mesalamine, steroids, or other medications) and it didn't work well enough, stopped working, or caused side effects.
- If you've used biologic medications (like anti-TNF drugs), you must have stopped them for a certain period before joining.
- You are willing to use effective birth control if you could become pregnant or father a child.
- You have adequate kidney, liver, and blood function, and do not have conditions like Crohn's disease, cancer, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ENC1018 for people with moderate-to-severe ulcerative colitis who haven't responded well to standard treatments. It aims to see if the drug is safe and works well.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This trial tests if older adults with ulcerative colitis who have been in remission for a long time can safely stop taking their immune-suppressing medication (thiopurine). It may help reduce medication side effects while keeping the disease under control.
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests whether a new drug called Hemay005 can help people with moderate to severe ulcerative colitis (a chronic bowel condition causing inflammation and symptoms like diarrhea and abdominal pain) who haven't responded well to or can't tolerate standard treatments. The goal is to reduce inflammation and improve symptoms.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.